Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
AZ-Daiichi, J&J-Legend, Samsung and more—FiercePharmaAsia
Friday, December 13, 2019
AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung execs.
FDA greenlights generics of Novartis' $3B MS star Gilenya
Friday, December 6, 2019
Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.
Which new MS drug do doctors like best? You might be surprised
Tuesday, November 19, 2019
A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.
Novartis' Gilenya staves off generics—for now—with injunction
Tuesday, June 25, 2019
With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.
Merck KGaA finally chalks up FDA nod for MS med Mavenclad
Monday, April 1, 2019
Rejected in 2011, Mavenclad won FDA approval with a label that's not ideal—but that doesn't necessarily hurt its blockbuster odds, says one analyst.
To focus as what CEO Vas Narasimhan calls “a medicines company,” Novartis made a series of M&A decisions in 2018.
Novartis' Gilenya tops Teva's Copaxone in head-to-head MS study
Thursday, October 11, 2018
Teva’s Copaxone has hung on to market share even in the face of oral competitors and generics. But Novartis aims to change that.
Novartis fires back at Gilenya generic challengers in court
Friday, July 20, 2018
In four suits filed before the Delaware District Court, Novartis is looking to block Gilenya generic entrance before 2027.
MS patent win boosts Novartis’ Gilenya, but helps Celgene, too
Friday, July 13, 2018
A patent ruling for Novartis will give Celgene time to secure FDA approval for its Gilenya rival and persuade physicians that it's a safer MS pill.